Vascular Endothelial Growth Factor-Induced Nitric Oxide- and PGI2-Dependent Relaxation in Human Internal Mammary Arteries
- 1 November 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 44 (5) , 615-621
- https://doi.org/10.1097/00005344-200411000-00016
Abstract
The role of the vascular endothelial growth factors (VEGF) receptors (KDR and Flt-1) and their characteristics in VEGF-induced vasodilation in human vessels is unclear. This study investigated the in vitro vasorelaxant effects of KDR-selective (KDR-SM) and Flt-1-selective mutants (Flt-1-SM) in the human internal mammary artery (IMA). IMA segments (n = 183) taken from 48 patients were studied in organ baths. The cumulative concentration (-12 to -8 log10M)-relaxation curves were established for VEGF, KDR-SM, Flt-1-SM, and placenta growth factor (PlGF) in the absence or presence of indomethacin (INDO, 7 microM), N-nitro-L-arginine (L-NNA, 300 microM), L-NNA + oxyhemoglobin (HbO, 20 microM), or INDO + L-NNA + HbO. The VEGF-induced relaxation was abolished in endothelium-denuded IMA. In the endothelium-intact vessel rings, VEGF (63.2 +/- 3.9%) induced significantly more (P < 0.001) relaxation than Flt-1-SM (28.5 +/- 4.3%, 95% CI 18.1-51.3%), and PlGF (26.0 +/- 4.7%, 95% CI 17.6-56.8%). The maximal relaxation induced by KDR-SM (53.0 +/- 4.0%) was only slightly less than that by VEGF (P = 0.075) but significantly more than that by Flt-1-SM (P = 0.001, 95% CI 7.8-41.1%). Pretreatment of INDO or L-NNA + HbO significantly (P < 0.001) inhibited the relaxation by VEGF (21.2 +/- 3.9% or 23.3 +/- 4.3%) and KDR-SM (9.8 +/- 8.2% or 10.1 +/- 17.8%). INDO + L-NNA + HbO completely inhibited the relaxation by VEGF, KDR-SM, or Flt-1-SM. KDR may be the dominant receptor in mediating the VEGF-mediated relaxation, which is regulated by both PGI2 and nitric oxide but probably not by endothelium-derived hyperpolarizing factor, in the human IMA. This study gives insight into the characteristics of the VEGF-mediated vasodilation and provides a scientific basis for potential clinical application of VEGF/KDR-SM in ischemic heart disease.Keywords
This publication has 26 references indexed in Scilit:
- Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor familyCardiovascular Research, 2001
- Role of vascular endothelial growth factor in the regulation of angiogenesisKidney International, 1999
- Vascular Endothelial Growth Factor/Vascular Permeability Factor Produces Nitric Oxide–Dependent HypotensionArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- VEGF Improves Myocardial Blood Flow but Produces EDRF-Mediated Hypotension in Porcine HeartsJournal of Surgical Research, 1996
- Effects of Vascular Endothelial Growth Factor on Hemodynamics and Cardiac PerformanceJournal of Cardiovascular Pharmacology, 1996
- Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesisNature Medicine, 1995
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995
- Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factorJournal of Vascular Surgery, 1995
- Enhanced revascularization of the ischemic limb by angiogenic therapy.Circulation, 1993
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989